Hosseini-Asl Seyed-Kazem, Mehrabani Davood, Karimi-Busheri Feridoun
Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Fars 71348-14336, Iran.
Stem Cell Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Fars 71348-14336, Iran.
J Clin Med. 2020 Dec 3;9(12):3922. doi: 10.3390/jcm9123922.
The worldwide epidemiology of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), still shows an increasing trend in Asia and Iran. Despite an improvement in the treatment landscape focused on symptomatic control, long-term colectomies have not decreased over the last 10-year period. Thus, novel therapies are urgently needed in clinics to supplement the existing treatments. Mesenchymal stem cells (MSCs) are multipotent adult stem cells with immunosuppressive effects, targeting IBD as a new treatment strategy. They have recently received global attention for their use in cell transplantation due to their easy expansion and wide range of activities to be engrafted, and because they are home to the mucosa of the intestine. Moreover, MSCs are able to differentiate into epithelial and other cells that can directly promote repair in the mucosal damages in UC. It seems that there is a need to deepen our understanding to target MSCs as a promising treatment option for UC patients who are refractory to conventional therapies. Here, we overviewed the therapeutic effects of MSCs in UC and discussed the achievements and challenges in the cell transplantation of UC.
包括克罗恩病（CD）和溃疡性结肠炎（UC）在内的炎症性肠病（IBD）的全球流行病学在亚洲和伊朗仍呈上升趋势。尽管在以症状控制为重点的治疗格局有所改善，但在过去10年中，长期结肠切除术的数量并未减少。因此，临床上迫切需要新的疗法来补充现有治疗方法。间充质干细胞（MSCs）是具有免疫抑制作用的多能成体干细胞，作为一种新的治疗策略靶向治疗IBD。由于其易于扩增、具有广泛的移植活性且能归巢至肠道黏膜，它们最近在细胞移植中的应用受到全球关注。此外，MSCs能够分化为上皮细胞和其他细胞，可直接促进UC黏膜损伤的修复。对于传统疗法难治的UC患者，似乎有必要加深对将MSCs作为一种有前景的治疗选择的理解。在此，我们概述了MSCs在UC中的治疗效果，并讨论了UC细胞移植的成果与挑战。
